Expert Conversations: How to Choose and Initiate a Novel Agent for Patients With CVD and Diabetes
While researchers originally explored sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP)-1\xa0receptor agonists\xa0for their impact on blood glucose, the two classes of agents were unexpectedly found to have cardiovascular benefits. In this podcast,\xa0Ralph Brindis, MD, MPH, interviews Laurence Sperling, MD, about implementing SGLT2 inhibitors and GLP-1\xa0receptor agonists into the\xa0treatment of\xa0patients with cardiovascular disease and diabetes. For more, click here: www.consultant360.com/cardiology